2023-505967-36-00CompletedPhase 1
A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Oct 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 7 Aug 2023
- Start date
- 15 Sept 2023
- Lead sponsor
- Betagenon AB
- Diseases
- Obesity, Type 2 diabetes
- EU CT number
- 2023-505967-36-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Completed |
| QPS Netherlands B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.